Inhibitory activity of analogues of luteinizing hormone-releasing hormone (LH-RH) in vitro and in vivo.

L. Ferland, F. Labrie, M. Savary, M. Beaulieu, D. H. Coy, E. J. Coy, Andrew V Schally

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Improved inhibitors of LH-RH are those which, beside removal of the histidine residue at position 2 of LH-RH, include replacement of glycine at position 6 by a D-amino acid. A still better modification is replacement of the histidine residue at position 2 by D-phenylalanine. As examples, when tested in pituitary cells in culture, [Des-His2]LH-RH, [Des-His2, D-Leu6]LH-RH, [Des-His2, D-Phe6]-LH-RH, [D-Phe2]LH-RH, [D-Phe2, D-Leu6]LH-RH and [D-Phe2, D-Phe6]LH-RH inhibit 50% of LH release induced by LH-RH at molar ratios (MR50S) of 3000, 500, 60, 1000, 150 and 25, respectively. [D-Phe2, D-Phe6, D-Phe7]LH-RH, [D-Phe2, Phe3, D-Phe6]LH-RH and [D-Phe2, Phe5, D-Phe6]LH-RH have MR50 values of respectively 400, 100, and 75. When evaluated in vivo, some of the mentioned structural modifications permit inhibition of LH-RH action at molar ratios lower than observed in vitro. At a 500 molar ratio, [D-Phe2, Phe5, D-Phe6]-LH-RH inhibits the plasma LH rise induced by LH-RH by 75% up to 5 h after its injection. When administered at 12.00 hours at the dose of 2 mg, this analogue inhibits the spontaneous pro-oestrus LH surge and ovulation by 85 and 75%, respectively.

Original languageEnglish
JournalClinical Endocrinology
Volume5 Suppl
StatePublished - Dec 1 1976
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
In Vitro Techniques
Histidine
Estrus
Ovulation
Phenylalanine
Glycine
Cell Culture Techniques

ASJC Scopus subject areas

  • Endocrinology

Cite this

Inhibitory activity of analogues of luteinizing hormone-releasing hormone (LH-RH) in vitro and in vivo. / Ferland, L.; Labrie, F.; Savary, M.; Beaulieu, M.; Coy, D. H.; Coy, E. J.; Schally, Andrew V.

In: Clinical Endocrinology, Vol. 5 Suppl, 01.12.1976.

Research output: Contribution to journalArticle

Ferland L, Labrie F, Savary M, Beaulieu M, Coy DH, Coy EJ et al. Inhibitory activity of analogues of luteinizing hormone-releasing hormone (LH-RH) in vitro and in vivo. Clinical Endocrinology. 1976 Dec 1;5 Suppl.
Ferland, L. ; Labrie, F. ; Savary, M. ; Beaulieu, M. ; Coy, D. H. ; Coy, E. J. ; Schally, Andrew V. / Inhibitory activity of analogues of luteinizing hormone-releasing hormone (LH-RH) in vitro and in vivo. In: Clinical Endocrinology. 1976 ; Vol. 5 Suppl.
@article{cfff40d74a64491788f1f4ce1a9d1c96,
title = "Inhibitory activity of analogues of luteinizing hormone-releasing hormone (LH-RH) in vitro and in vivo.",
abstract = "Improved inhibitors of LH-RH are those which, beside removal of the histidine residue at position 2 of LH-RH, include replacement of glycine at position 6 by a D-amino acid. A still better modification is replacement of the histidine residue at position 2 by D-phenylalanine. As examples, when tested in pituitary cells in culture, [Des-His2]LH-RH, [Des-His2, D-Leu6]LH-RH, [Des-His2, D-Phe6]-LH-RH, [D-Phe2]LH-RH, [D-Phe2, D-Leu6]LH-RH and [D-Phe2, D-Phe6]LH-RH inhibit 50{\%} of LH release induced by LH-RH at molar ratios (MR50S) of 3000, 500, 60, 1000, 150 and 25, respectively. [D-Phe2, D-Phe6, D-Phe7]LH-RH, [D-Phe2, Phe3, D-Phe6]LH-RH and [D-Phe2, Phe5, D-Phe6]LH-RH have MR50 values of respectively 400, 100, and 75. When evaluated in vivo, some of the mentioned structural modifications permit inhibition of LH-RH action at molar ratios lower than observed in vitro. At a 500 molar ratio, [D-Phe2, Phe5, D-Phe6]-LH-RH inhibits the plasma LH rise induced by LH-RH by 75{\%} up to 5 h after its injection. When administered at 12.00 hours at the dose of 2 mg, this analogue inhibits the spontaneous pro-oestrus LH surge and ovulation by 85 and 75{\%}, respectively.",
author = "L. Ferland and F. Labrie and M. Savary and M. Beaulieu and Coy, {D. H.} and Coy, {E. J.} and Schally, {Andrew V}",
year = "1976",
month = "12",
day = "1",
language = "English",
volume = "5 Suppl",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Inhibitory activity of analogues of luteinizing hormone-releasing hormone (LH-RH) in vitro and in vivo.

AU - Ferland, L.

AU - Labrie, F.

AU - Savary, M.

AU - Beaulieu, M.

AU - Coy, D. H.

AU - Coy, E. J.

AU - Schally, Andrew V

PY - 1976/12/1

Y1 - 1976/12/1

N2 - Improved inhibitors of LH-RH are those which, beside removal of the histidine residue at position 2 of LH-RH, include replacement of glycine at position 6 by a D-amino acid. A still better modification is replacement of the histidine residue at position 2 by D-phenylalanine. As examples, when tested in pituitary cells in culture, [Des-His2]LH-RH, [Des-His2, D-Leu6]LH-RH, [Des-His2, D-Phe6]-LH-RH, [D-Phe2]LH-RH, [D-Phe2, D-Leu6]LH-RH and [D-Phe2, D-Phe6]LH-RH inhibit 50% of LH release induced by LH-RH at molar ratios (MR50S) of 3000, 500, 60, 1000, 150 and 25, respectively. [D-Phe2, D-Phe6, D-Phe7]LH-RH, [D-Phe2, Phe3, D-Phe6]LH-RH and [D-Phe2, Phe5, D-Phe6]LH-RH have MR50 values of respectively 400, 100, and 75. When evaluated in vivo, some of the mentioned structural modifications permit inhibition of LH-RH action at molar ratios lower than observed in vitro. At a 500 molar ratio, [D-Phe2, Phe5, D-Phe6]-LH-RH inhibits the plasma LH rise induced by LH-RH by 75% up to 5 h after its injection. When administered at 12.00 hours at the dose of 2 mg, this analogue inhibits the spontaneous pro-oestrus LH surge and ovulation by 85 and 75%, respectively.

AB - Improved inhibitors of LH-RH are those which, beside removal of the histidine residue at position 2 of LH-RH, include replacement of glycine at position 6 by a D-amino acid. A still better modification is replacement of the histidine residue at position 2 by D-phenylalanine. As examples, when tested in pituitary cells in culture, [Des-His2]LH-RH, [Des-His2, D-Leu6]LH-RH, [Des-His2, D-Phe6]-LH-RH, [D-Phe2]LH-RH, [D-Phe2, D-Leu6]LH-RH and [D-Phe2, D-Phe6]LH-RH inhibit 50% of LH release induced by LH-RH at molar ratios (MR50S) of 3000, 500, 60, 1000, 150 and 25, respectively. [D-Phe2, D-Phe6, D-Phe7]LH-RH, [D-Phe2, Phe3, D-Phe6]LH-RH and [D-Phe2, Phe5, D-Phe6]LH-RH have MR50 values of respectively 400, 100, and 75. When evaluated in vivo, some of the mentioned structural modifications permit inhibition of LH-RH action at molar ratios lower than observed in vitro. At a 500 molar ratio, [D-Phe2, Phe5, D-Phe6]-LH-RH inhibits the plasma LH rise induced by LH-RH by 75% up to 5 h after its injection. When administered at 12.00 hours at the dose of 2 mg, this analogue inhibits the spontaneous pro-oestrus LH surge and ovulation by 85 and 75%, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0017038758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017038758&partnerID=8YFLogxK

M3 - Article

VL - 5 Suppl

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

ER -